摘要
目的:观察乳腺癌患者新辅助化疗前后细胞增殖及凋亡的变化,分析与化疗疗效的关系。方法:51例乳腺癌患者术前经Mammotome穿刺活检确诊,在CEF方案新辅助化疗前及化疗2个周期后分别进行癌组织中Ki-67的免疫组织化学染色和TUNEL原位细胞凋亡检测,并评价化疗疗效。结果:新辅助化疗前Ki-67阳性表达率及凋亡指数(AI)分别为23.2%和34.1%,化疗2个周期后Ki-67阳性表达率及AI分别为7.8%和67.5%,两者差异有统计学意义,P=0.004,P=0.006;化疗疗效临床CR5例,PR40例,SD6例,无疾病进展期病例,新辅助化疗疗效与Ki-67表达下降及肿瘤细胞凋亡增加显著相关。结论:新辅助化疗可明显抑制乳腺癌细胞的增殖,诱导凋亡,与化疗疗效密切相关。
OBJECTIVE: To observe the changes of apoptosis and proliferation of breast cancer after neoadjuvant chemotherapy and discuss the relationship with chemotherapy. METHODS: Fifty-one cases of breast cancer were diagnosed by Mammotome. Expressions of Ki 67 and AI were detected by immunohistochemistry and TUNEL respectively before and after 2 cycles of chemotherapy. The effectiveness of chemotherapy was also observed after the chemotherapy. RESULTS: Before neoadjuvant chemotherapy, the expression rates of Ki-67 and AI were 23. 2% and 34. 1%, respectively. There was a statistic significance compared with the expression levels of Ki-67 and AI after the chemotherapy (7. 8%- 67. 5% ), P=0.004 & P= 0. 006. The complete response and partial response were achieved in 5 patients and 40 patients, respectively. There were no disease progressed (PD) cases. The expressions of Ki-67 and AI were closely related to patients' response to neoadjuvant chemotherapy. CONCLUSION: Neoadjuvant chemotherapy can inhibit the proliferation of breast cancer cell and induce apoptosis, which are closely related to the effectiveness of chemotherapy.
出处
《中华肿瘤防治杂志》
CAS
2007年第14期1085-1087,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
陕西省自然科学基金(2003C2053)
关键词
乳腺肿瘤/药物疗法
新辅助化疗
细胞增殖
凋亡
breast neoplasms/drug therapy
neoadjuvant chemotherapy
cell proliferation
apoptosis